https://www.facebook.com/479889999064071/

Afripharm Group|Afripharm Medicals (Ltd), Enugu (2026)

21/04/2026

Access to medicines in emerging markets is not a demand problem.

It is a systems problem.

■ Fragmented supply chains.
■ Limited visibility.
■ Weak verification to tackle counterfeit problems.

These gaps slow the movement of safe, reliable products and create space for inefficiency and risk.

AfriPharm Medicals Group is building infrastructure to address this at scale.

We began as a pharmaceutical distribution and market access company in Nigeria. That foundation remains. We move products, open markets, and connect manufacturers to real demand.

Working inside the market revealed a deeper layer of problems embedded inside the emerging health markets.

The constraint is not supply. It is coordination, visibility, and trust across the system.

That insight is shaping what AfriPharm is becoming.

Today, we operate a hybrid model.

■ A commercial distribution network on one side.
■ A digital infrastructure layer on the other.

The system is built across three (3) connected layers.

■ Distribution.
Real movement of products across active markets. Demand is observed, not assumed.

■ Intelligence.
An AI-driven layer that forecasts demand, reduces stock imbalances, and improves supply chain decisions.

■ Trust.
Track and trace systems that support product verification, reduce counterfeit risk, and strengthen confidence across the ecosystem.

Each layer reinforces the other.

■ Distribution generates data.
■ Data sharpens decisions.
■ Better decisions strengthen the system.

Nigeria is our base.
The opportunity is regional. With its scale and position, Nigeria serves as a natural gateway into West Africa.

Systems that perform here can extend across borders.

This is beyond building a larger distribution company. It is more about building an infrastructure layer that connects manufacturers, regulators, and markets in a way that works in practice and scales across regions.

The next phase of healthcare in emerging markets will not be defined by isolated interventions.

It will be shaped by systems that connect supply, data, and trust.

AfriPharm Medicals Group is being built with that in mind.

17/03/2026

Africa Pharmaceutical Market
Supply Gap and Market Entry Implications |

Africa imports about 70-90% of the medicines it consumes.

The pharmaceutical market is estimated at $50B to $70B, with the population projected to reach 2.5 billion by 2050.

Local manufacturing currently meets only 10 to 30% of demand, with production concentrated in a limited number of countries, including Egypt, South Africa, Morocco, Nigeria, Kenya, and Tunisia.

This creates a persistent supply gap driven by

■ limited local production capacity
■ extended cross-border supply chains
■ fragmented distribution systems

The result is continued dependence on imports, exposure to supply disruptions, and uneven quality control across markets.

Nigeria represents the largest pharmaceutical market in West Africa, with

■ population above 220 million
■ market size of about $4B
■ import dependence above 70%

Nigeria also provides access to the Economic Community of West African States, a regional market of about 420 million people with an estimated pharmaceutical value of $12B to $15B.

For pharmaceutical manufacturers, Nigeria offers a practical entry point into both a large domestic market and a wider regional distribution network.

Market entry requires
■ regulatory approval through the National Agency for Food and Drug Administration and Control
■ technical dossier preparation
■ compliance with Good Manufacturing Practice standards
■ local distribution partnerships

AfriPharm Medicals Group supports international manufacturers across these areas, enabling structured entry into Nigeria and expansion into West Africa.

The long-term opportunity in Africa will depend on the development of reliable local supply systems aligned with growing demand.

(c) Bright Chimezie Irem
Afripharm Group|Afripharm Medicals (Ltd)

17/03/2026

📊 Africa imports up to 90% of the medicines circulating in its pharmaceutical market | Bright Chimezie Irem

This means that "Africa imports 90% of the medicines it consumes."

The continent’s pharmaceutical market is already estimated at between $50B and $70B, and Africa’s population is projected to reach about 2.5 billion by 2050.

Yet local pharmaceutical manufacturing still meets only about 10-30% of the demand for medicines.

Production capacity exists, but it is uneven and concentrated in a few countries, including Egypt, South Africa, Morocco, Nigeria, Kenya, and Tunisia.

That gap affects both business and public health.

Heavy reliance on imports makes access to medicine more vulnerable to shipping delays, foreign exchange (FX) pressure, border disruptions, and weak quality control along long supply routes.

Africa is already a major pharmaceutical market. What remains underdeveloped is the depth of local manufacturing and stronger distribution or supply chain systems.

Nigeria is central to that situation.

With more than 220 million people and a pharmaceutical market valued at about $4B, Nigeria is the largest pharmaceutical market in West Africa.

Nigeria is also connected as a viable market access window to the Economic Community of West African States (ECOWAS), a regional market of about 420 million people with an estimated pharmaceutical value of $12B to $15B.

For large pharmaceutical product manufacturers, that means a strong position in Nigeria can open access to both a large domestic market and a wider regional network.

Getting into Africa’s Pharmaceutical market, however, requires more than product interest.

It requires regulatory approval from the National Agency for Food and Drug Administration and Control (NAFDAC, Nigeria), preparation of a technical dossier, compliance with Good Manufacturing Practice (GMP) standards, and reliable distribution partners on the ground.

Afripharm Group|Afripharm Medicals (Ltd) works with international pharmaceutical manufacturers through these steps: from regulatory planning to market-entry support and distribution access.

The long-term opportunity in Africa will depend on who helps build dependable supply systems close to demand.

Manufacturers that move early and build the right local network and partnerships will be better placed to grow across the continent.

Connect with AfriPharm Medicals Group to explore entry into Nigeria and the wider West African pharmaceutical market.

(c) Bright Chimezie Irem
AfriPharm Medicals Group

16/03/2026

📊 Nigeria imports more than 70% of the medicines it consumes.

Yet the country has a population of over 200 million people and a pharmaceutical market valued at roughly $4B.

For global pharmaceutical manufacturers, this creates one of the largest opportunities for medicine supply in Africa.
But the practical question is simple.

Which medicines does Nigeria need the most?

Below are the therapeutic categories that dominate pharmaceutical demand nationwide.

Pain relief and analgesics
Pain medicines account for about 25% of medicine use nationwide.

High-demand products include Paracetamol, Ibuprofen, and Diclofenac.

These medicines move quickly through hospitals, pharmacies, and community medicine outlets.

Antibiotics and anti-infectives
Antibiotic medicines account for roughly 15% of total medicine demand due to the ongoing burden of infectious diseases.

Common products include Amoxicillin, Metronidazole, and Ciprofloxacin.
Antimalarial medicines

Nigeria carries one of the highest malaria burdens globally.

Antimalarial therapies account for about 14% of total medicine demand, with Artemisinin combination therapies such as Artemether-Lumefantrine widely used.

Cardiovascular medicines
Hypertension and cardiovascular disease are increasing rapidly as urbanization and lifestyle patterns change.

Common therapies include Amlodipine, Atenolol, and Telmisartan.

Diabetes medicines
Diabetes prevalence continues to rise across West Africa.

Oral medicines such as Metformin and Glibenclamide remain widely prescribed.

Multivitamins and nutritional supplements

Multivitamins account for roughly 15% of retail pharmaceutical demand and are widely available in pharmacies and over-the-counter medicine outlets.

What this means for global manufacturers

Nigeria’s pharmaceutical market is driven by strong demand for essential medicines and chronic disease treatments.

Manufacturers focusing on anti-infectives, antimalarials, pain medicines, cardiovascular therapies, diabetes medicines, and nutritional supplements are positioned to access immediate commercial demand.

How AfriPharm Medicals Group supports market entry

AfriPharm Medicals Group works with international manufacturers to translate this demand into successful market entry.

Our work includes regulatory pathway planning with the National Agency for Food and Drug Administration and Control, dossier preparation in the Common Technical Document format, manufacturing site readiness for Good Manufacturing Practice inspections, submission and tracking through the NAFDAC Product Administration and Monitoring System, distribution access across hospitals and pharmacy networks, and post-approval compliance, including renewals and pharmacovigilance.

With the right regulatory and distribution strategy, manufacturers can move from market assessment to product presence in Nigeria within predictable timelines.

Connect with AfriPharm Medicals Group to explore opportunities in Nigeria’s $4B pharma market.

16/03/2026

📊 Nigeria has the largest pharmaceutical market in West Africa | Bright Chimezie Irem

More than 230 million people and a pharmaceutical market valued at above $4B.

Over 70% of medicines used in Nigeria are imported.

That alone tells a clear story.

Demand exists. Supply still depends heavily on imports.

But the opportunity extends beyond Nigeria.

Nigeria is at the center of the Economic Community of West African States, a regional bloc of 15 countries with a population of about 420 million.

For pharmaceutical manufacturers evaluating Africa, the information in my article here should be critical.

A company that establishes regulatory approval and distribution in Nigeria gains access to a much wider regional market.

Across West Africa, demand for medicine continues to rise as population growth, urban expansion, and the prevalence of chronic diseases put pressure on healthcare systems.

Market estimates place the West African pharmaceutical market at $12B to $15B, with Nigeria accounting for the largest share.

This is why many global manufacturers treat Nigeria as their first commercial foothold in the region.

From here, distribution networks often extend into nearby markets such as Ghana, Côte d’Ivoire, Senegal, Benin, Togo, and Cameroon.

Nigeria functions as a regional gateway.

Ports, wholesale medicine markets, and cross-border trade routes help facilitate the movement of pharmaceutical products throughout the region.

For international pharmaceutical manufacturers, part of the real business challenge is rarely demand. It is going through the regulatory approval and building reliable distribution partnerships on the ground.

AfriPharm Medicals Group works with global pharmaceutical manufacturers on this process.

Our work includes regulatory planning with the National Agency for Food and Drug Administration and Control, dossier preparation, manufacturing site readiness for Good Manufacturing Practice (GMP) inspections, and distribution access across hospital and pharmacy networks in Nigeria.

Done properly, Nigeria becomes a practical launch point into one of Africa’s fastest-growing pharmaceutical regions.

Connect with AfriPharm Medicals Group to explore partnership opportunities in Nigeria and across the West African pharmaceutical market.

(c) Bright Chimezie Irem
Fellow Global Citizen ✨️

16/03/2026

In many conversations about healthcare, attention naturally turns to hospitals, clinicians, and medicines.

Yet the reliability of care often depends on something less visible.

It depends on the systems that move medicines through the supply chain and ensure that treatments reach the facilities where patients are waiting.

Across several African countries, medicines may be available in national markets while hospitals and clinics still struggle to obtain them consistently.

When supply networks break down, health workers are forced to improvise, leading to delayed treatment.

Seeing this gap shaped the direction of my work.

Over the past several years, I have focused on strengthening the operational systems that support healthcare delivery, particularly the pharmaceutical supply chains that connect manufacturers, distributors, hospitals, and local clinics.

Through AfriPharm Medicals Group and related initiatives, including AlphaMed Projects, Climate Resource Center (CRC), and the Health for Humanity Foundation, my work centers on improving how these networks function so that essential medicines reach the communities that depend on them.

Progress in this area requires careful project leadership. Health systems rarely improve through ideas alone. Reliable results come from disciplined ex*****on, coordination across institutions, and systems that function consistently within local realities.

My professional journey has included experiences such as the Mandela Washington Fellowship for Young African Leaders and the Youth Innovate initiative connected to the The World Bank Group (WBG). These experiences reinforced an important observation.

When health systems operate well, the systems behind them often go unnoticed. When those systems fail, the consequences are felt immediately by patients and healthcare workers.

My work continues to focus on building practical supply chain and operational solutions that strengthen healthcare delivery and improve reliable access to essential medicines across Africa.

Healthcare ultimately depends not only on the dedication of clinicians, but also on the strength of the systems that support their work every day.

Bright Chimezie Irem
AfriPharm Medicals Grp.

16/03/2026

Nigeria’s Fake Drug Crisis Is More of a Supply Chain Problem | Bright Chimezie Irem

Nigeria’s healthcare system faces a persistent threat.
Many patients remain unsure whether the medicines they purchase are genuine.

Counterfeit and substandard medicines continue to circulate in informal medicine markets and weak distribution channels.
Nigeria has battled falsified medicines for decades.

The World Health Organization (WHO) estimates that about 10% of medical products in low- and middle-income countries may be substandard or falsified.

The consequences are serious.

Patients seeking treatment may receive ineffective medicines.

● Infections become harder to treat.
● Drug resistance increases.
● Public trust in healthcare systems weakens.

Nigeria has strengthened regulatory oversight in recent years through the National Agency for Food and Drug Administration and Control (National Agency for Food and Drug Administration and Control (NAFDAC)).

Surveillance systems, inspections, and supply monitoring have improved enforcement.

Regulation alone will not eliminate falsified medicines.

The root problem lies in the medicine supply chain.

Nigeria imports more than 70% of the medicines it consumes.

Long supply routes, fragmented distribution, and informal medicine markets create opportunities for counterfeit and damaged products to enter circulation.

Counterfeit medicines are not driven only by criminal activity.

Weak supply systems allow falsified products to enter legitimate markets.

Countries that reduced counterfeit medicines strengthened regulation, formalized distribution channels, and expanded domestic pharmaceutical manufacturing.

Reliable distribution systems reduce counterfeit pe*******on.

Stronger pharmaceutical supply chains bring traceability, quality assurance, and accountable medicine distribution.

Nigeria has the market size, regulatory institutions, and regional influence to lead improvements across West Africa.

Strengthening medicine supply systems will protect patients and restore confidence in healthcare delivery.

Bright Chimezie Irem
Medicals Grp

10/09/2025

Nigeria Drug Registration Pathways – Clear Guide

The National Agency for Food and Drug Administration and Control (NAFDAC) manages medicine importation and marketing in Nigeria.

The right pathway helps manufacturers avoid delays and enter the market with confidence.

1. Full Registration with NAFDAC

This is for new manufacturers whose products and facilities have not yet been audited.
Outcome Marketing Authorization is valid for 5 years.

Timeline
About 6–9 months, including dossier review, lab testing, and Good Manufacturing Practice (GMP) inspection.

2. Renewal of Marketing Authorization

For already registered products approaching expiry.
Outcome Extension for another 5 years.

Timeline
Apply 3–6 months before expiry with safety and pharmacovigilance data.

3. Post Approval Changes and Line Extensions

This is for changes in site, process, composition, packaging, or when adding new strengths.

Outcome
Approved variation or extension keeps the license valid.

4. Import Permit for Clinical Trials

For investigational products in approved trials.

Outcome
Permit to import limited quantities.

Timeline requires ethics approval and NAFDAC trial authorization, usually within a few weeks.

5. Port Fast Track Clearance
For registered products or materials.

Outcome: Quicker clearance within 24–48 hours.

6. Pre-Shipment Inspection and CRIA
For imports from countries like India and China, where NAFDAC recognizes accredited agents.

Outcome: Smoother border clearance and better documentation.

7. Technical Standards
Applications must go through the NAFDAC Product Administration and Monitoring System (NAPAMS) in Common Technical Document (CTD) format.

Module 1 requires corporate records, a Certificate of Pharmaceutical Product, a GMP certificate, and a Power of Attorney.

Generics must show bioequivalence or a valid waiver.

How AfriPharm Medicals Group Helps

AfriPharm Medicals Group partners with international manufacturers to:

Confirm eligibility and product class before filing
Run gap analysis on dossiers and documents
Prepare sites for GMP inspections.

File and track submissions on NAPAMS

Coordinate lab tests, CRIA, and port clearance

Maintain renewals, pharmacovigilance, and variations

With AfriPharm, global manufacturers can move from first interest to product launch in Nigeria within predictable timelines.

Connect with AfriPharm Medicals Group today to explore regulatory and distribution opportunities in Nigeria’s $4B pharmaceutical market.

07/09/2025

Nigeria’s Pharma & Health Market! Did you know?

Nigeria’s pharmaceutical market is valued at $4 billion and continues to grow yearly.

With over 250 million people and rising rates of diabetes, cancer, and cardiovascular disease, demand for quality medicines is increasing faster than domestic supply can meet.

Here are the hard facts:

More than 70% of the medicines on the shelves are imported.

The market is estimated at around $4 billion, driven by unmet health needs and population growth.

This means opportunity is right in front of us.

Nigeria needs reliable access to medicines.

Buyers are ready.

The delivery networks exist.

What’s missing is a partner who can enable smooth entry.

AfriPharm Medicals Group brings that partner to life:

• We offer a design-to-fit local distribution framework

• We guide manufacturers through the NAFDAC process efficiently

• We connect you/manufacturers with hospitals, pharmacies, and wholesale buyers

Suppose your company manufactures quality medicines in India, the USA, Egypt, China, Turkey, or Europe.

In that case, AfriPharm can help you enter the Nigerian market within months, backed by regulatory clarity and supply assurance.

Message us today to start your market entry journey.

15/08/2025

Nigeria’s pharmaceutical market. What matters now | Bright Chimezie Irem

Nigeria is the largest single pharmaceutical market in sub-Saharan Africa.

The market size is about $4B, and growth is near 9% a year.

Most medicines are imported, which creates headroom for manufacturers who combine capacity with strong local ex*****on.

Imports account for 70% of medicines used in Nigeria. Local plants run below capacity, so scale can shift quickly when a capable partner model aligns with precise regulation.

Regulation is shifting practically. Through NAPAMS and new guidance, NAFDAC has tightened and clarified device and product pathways. This reduces time and rework for entrants with complete dossiers and robust quality systems.

Coverage is expanding across programs. The National Health Insurance Authority (NHIA) created a stronger enrollment and purchasing power platform.

Government reports show that new enrollees have been added over the past 18 months, which improves the visibility of the demand for essential medicines and devices.

Policy support is strengthening.

Nigeria introduced tax measures to encourage local production and reduce import dependence.

World Health Organization (WHO) prequalification wins among local firms show quality progress and export potential.

Africa-wide demand is rising through 2030, reinforcing Nigeria’s role as a gateway market.

What wins in this market

■ Provide proven quality and reliable supply

■ Secure fast and clean registration and strong post-market vigilance

■ Invest in clinician education and hospital access, not only price lists

■ Compete in tenders with transparent service levels and high fill rates

■ Use risk-sharing structures that align incentives for sustained share gains

15/08/2025

Nigeria is the largest single pharmaceutical market in sub-Saharan Africa, and the opportunity in medical disposables is both immediate and measurable.

85% of Nigerian hospitals' syringes, catheters, infusion sets, and procedure packs are imported. Local production covers the rest, leaving space for manufacturers combining capacity with local ex*****on.

Hospital demand is shifting toward safe injection, sterile urology, and IV therapy products, while procurement reforms raise the bar on documentation and quality.

Recent regulatory updates from NAFDAC have streamlined the device pathway with dossier screening, NAPAMS onboarding, and clear submission channels, helping serious partners move faster.

Even in tight budget cycles, health spending remains a priority.

Nigeria’s pull within the broader ECOWAS market continues to drive demand from public programs, teaching hospitals, and the private sector.

For manufacturers looking at West Africa, the route is straightforward:

■ Bring proven quality & scale.

■ Match it with local registration, clinician engagement & tender capability.

■ Align incentives for long-term market share rather than one-off shipments.

That is where outcomes compound.

Afripharm Group|Afripharm Medicals (Ltd)

21/04/2026

17/03/2026

17/03/2026

16/03/2026

16/03/2026

16/03/2026

16/03/2026

10/09/2025

07/09/2025

15/08/2025

15/08/2025

Address

Website

Alerts

Contact The Practice

Shortcuts

Share

Category